About BARDA
BARDA is a company based in United States. It operates as a Professional Services. BARDA offers products and services including Medical Countermeasures Development, Pandemic Vaccines and Adjuvants, and Diagnostics and Devices.
- Headquarter United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website MedicalCountermeasures.gov
- Social LinkedIn Threads
Products & Services of BARDA
BARDA offers a comprehensive portfolio of products and services, including Medical Countermeasures Development, Pandemic Vaccines and Adjuvants, and Diagnostics and Devices.
Medical countermeasures are developed for public health emergencies.
Vaccines and adjuvants are created for pandemic preparedness.
Diagnostics and devices are supported for health security.
Similar companies to BARDA
10 companies that operate in the same segment as BARDA (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BARDA
BARDA is headquartered in United States.
BARDA, part of the U.S. Department of Health Human Services, is dedicated to enhancing national preparedness for public health emergencies. Medical countermeasures are developed and supported through various programs targeting chemical, biological, radiological, and nuclear threats. Solutions are advanced from research to clinical trials and manufacturing, covering sectors like antimicrobials, vaccines, diagnostics, and emergency response. Partnerships are fostered with innovators to protect against emerging infectious diseases and pandemics.
BARDA offers Medical Countermeasures Development, Pandemic Vaccines and Adjuvants, and Diagnostics and Devices.